A Phase 2/3 interventional study of Propionic acid 1000 mg capsule and Placebo in Multiple Sclerosis, sponsored by Salzburger Landeskliniken. Completed at 1 site in Austria. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Salzburger Landeskliniken · Phase 2/3, Interventional, and Treatment
Among 78 studies in Multiple Sclerosis with a site in Austria — 2 open to participants now, 10 under way, 7 of them phase 3. Multiple Sclerosis · Austria.
Among the 78 studies in Multiple Sclerosis with a site in Austria, this one is the 55th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2024, is the only one in phase 2/3, and was the 72nd registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's enrollment of 101 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →2 of the 78 studies in Multiple Sclerosis with a site in Austria are open now.
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 36 · Phase 4 10
First in 2002; this study’s year is marked. 4 started in 2024.
Median enrollment 534 across the 63 interventional studies, 312 across the 15 observational. Of the 65 that completed or were terminated, 42 (65%) have results posted.
67 of 78 have an industry lead sponsor. The 10 most frequent:
Salzburger Landeskliniken is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Salzburger Landeskliniken has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
Among the 78 studies in Multiple Sclerosis with a site in Austria, from their registry updates:
The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis (MS).
This is a single-center, double-blinded, randomized trial. One hundred multiple sclerosis (MS) patients will be randomly assigned in a 2:1 ratio to receive either 100 mg of propionic acid or a placebo over a period of 90 days. Outcome measures will encompass NfL and GFAP levels, fatigue scores, quality of life assessments, and physical examinations. Additionally, subgroup analysis will involve the evaluation of MRI and MEG data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: Propionic acid 1000 mg capsule
Dietary Supplement: Placebo
Patients will be assigned to propionic acid or placebo as add on MS treatment.
Patients will be assigned to propionic acid or placebo as add on MS treatment.
Serum neurofilament light chain (NfL)
assessed as pg/ml
Time frame: 90 days
Serum glial fibrillary acid protein (GFAP)
assessed as pg/ml
Time frame: 90 days
Fatigue Scale for Motor and Cognitive Functions (FSMC)
Fatigue Score, Questionnaire
Time frame: 90 days
Walking test, 10 meters distance
assessed as seconds
Time frame: 90 days
cerebral MRI
number of rim lesions; subgroup analysis
Time frame: 90 days
36-Item Short Form Health Survey (SF-36)
Quality of Life, Questionnaire
Time frame: 90 days
Magnetoencephalography (MEG)
Assessing neuronal slowing proposed as a marker of cognitive impairment in MS; Subgroup analysis
Time frame: 90 days
9-hole peg test
assessed in seconds
Time frame: 90 days
Ran from May 2024 to primary completion in Sep 2024, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Salzburger Landeskliniken